The Phase I trial of Arecor’s ultra-concentrated ultra-rapid insulin, AT278, has met all primary and secondary endpoints, demonstrating a superior pharmacokinetic (PK) and pharmacodynamic (PD) profile to a comparable dose of lower concentration of NovoRapid (NovoNordisk’s gold standard rapid acting insulin).
20 Sep 2021
AT278 Phase I delivers better than expected results
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
AT278 Phase I delivers better than expected results
Arecor Therapeutics PLC (AREC:LON) | 136 0 0.0% | Mkt Cap: 41.8m
- Published:
20 Sep 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
2
The Phase I trial of Arecor’s ultra-concentrated ultra-rapid insulin, AT278, has met all primary and secondary endpoints, demonstrating a superior pharmacokinetic (PK) and pharmacodynamic (PD) profile to a comparable dose of lower concentration of NovoRapid (NovoNordisk’s gold standard rapid acting insulin).